Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

Pulmonary hypertension and lung diseases: a suggestion for revision of the clinical classification

I. Tsangaris, S. Orfanos, D. Bouros
European Respiratory Journal 2010 35: 700-701; DOI: 10.1183/09031936.00179709
I. Tsangaris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Orfanos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Bouros
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editors:

We read with great interest the new clinical classification of pulmonary hypertension (PH) 1, that represents a tremendous and successful effort to summarise the existing evidence of a rapidly evolving field in a physician-friendly manner. We want to focus on the inclusion of sarcoidosis, pulmonary Langerhans cells histiocytosis (PCLH) and lymphangioleiomyomatosis (LAM) in the subgroup of PH with unclear or multifactorial aetiologies (Group 5). Although raising such an issue might seem pedantic, we believe that there are good reasons for reconsidering the group place of these disorders.

Interstitial lung diseases (ILD) consist of disorders of known (e.g. collagen vascular disease, environmental, drug-induced) as well as unknown causes. The latter include idiopathic interstitial pneumonias, granulomatous lung disorders (e.g sarcoidosis), and other forms of ILDs, including LAM, PLCH and eosinophilic pneumonia 2.

Group 5.2 diseases may have a systemic component but their pulmonary manifestations far outnumber the manifestations of any other system. They mainly represent diffuse parenchymal lung diseases with distinctive and well-defined clinicopathological features that can affect all aspects of lung anatomy (interstitium, airspaces, peripheral airways and vessels), resulting in PH in a proportion of patients. Sarcoidosis presents with associated lung involvement in up to 95% of cases 3 and respiratory failure is the most common cause of death in Europe and the USA. Furthermore, mean pulmonary artery pressure has been significantly correlated with diffusion deficit and pulmonary vascular resistance with arterial oxygen tension in this setting 4. PCLH is an ILD, preferentially affecting heavy smokers. LAM usually presents with cystic degeneration of the lungs and is often misdiagnosed initially as asthma or chronic obstructive pulmonary disease. It is a fact that the pathogenesis of PH for these disease entities is incompletely understood and may be multifactorial, but the same is true for all other ILDs 5. Not surprisingly, no PAH-specific therapies have been approved for all these disease entities.

Indeed, the current classification moves to the right direction by adopting a clinically meaningful way of thinking and avoiding unnecessary pathophysiological implications; PH owing to left heart disease (Group 2) and chronic thromboembolism (Group 4) are good examples. In this context, sarcoidosis, PLCH and LAM (Group 5.2) represent disorders that, according to the current evidence, are associated with PH mainly due to lung involvement and, therefore, we propose their inclusion in the third category (PH owing to lung disease and/or hypoxia) in any future classification scheme.

Statement of interest

None declared.

    • © ERS Journals Ltd

    References

    1. ↵
      Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009;34:1219–1263.
      OpenUrlFREE Full Text
    2. ↵
      Travis WD, King TE, Bateman ED, et al. ATS/ERS international multidisciplinary consensus classification of idiopathic interstitial pneumonias. General principles and recommendations. Am J Respir Crit Care Med 2002;165:277–304.
      OpenUrlCrossRefPubMed
    3. ↵
      Baughman RP, Teirstein AS, Judson MA, et al. Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885–1889.
      OpenUrlCrossRefPubMedWeb of Science
    4. ↵
      Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006;61:68–74.
      OpenUrlAbstract/FREE Full Text
    5. ↵
      Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008;31:1357–1367.
      OpenUrlAbstract/FREE Full Text
    View Abstract
    PreviousNext
    Back to top
    View this article with LENS
    Vol 35 Issue 3 Table of Contents
    European Respiratory Journal: 35 (3)
    • Table of Contents
    • Table of Contents (PDF)
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Pulmonary hypertension and lung diseases: a suggestion for revision of the clinical classification
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Pulmonary hypertension and lung diseases: a suggestion for revision of the clinical classification
    I. Tsangaris, S. Orfanos, D. Bouros
    European Respiratory Journal Mar 2010, 35 (3) 700-701; DOI: 10.1183/09031936.00179709

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Pulmonary hypertension and lung diseases: a suggestion for revision of the clinical classification
    I. Tsangaris, S. Orfanos, D. Bouros
    European Respiratory Journal Mar 2010, 35 (3) 700-701; DOI: 10.1183/09031936.00179709
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Statement of interest
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Treatable traits approach in interstitial lung disease
    • Reply: Treatable traits approach in interstitial lung disease
    • TB screening in migrants to the EU/EEA and UK
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2023 by the European Respiratory Society